NCT01299415View on ClinicalTrials.gov

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

September 30, 2010

Conditions
Solid Tumors
Interventions
DRUG

Vadimezan™

Trial Locations (4)

46202

Univ. of Indiana School of Medicine/Simon Cancer Center, Indianapolis

55455

Masonic Cancer Center/ Clinical Trials Office, Minneapolis

63110

Washington University School of Medicine/Siteman Cancer Center, St Louis

78229

Cancer Therapy & Research Center, San Antonio

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY